Is Novo Nordisk facing its 'Nokia moment'? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forces
Novo Nordisk, Denmark's pharma powerhouse, has seen its stock plunge from record highs as fierce competition, slowing growth, and market shifts test its dominance in the global diabetes and obesity drug market.
Tired of too many ads?
Remove Ads
Intensifying Competitive Pressures
Compounded versions from U.S. pharmacies —driven by FDA shortages—have eaten into branded sales.
—driven by FDA shortages—have eaten into branded sales. Eli Lilly's Zepbound and Mounjaro are gaining prescription share. As of July 2025, Zepbound holds 59% of prescriptions compared to Wegovy's 40%, signaling a material shift in market preference.
Tired of too many ads?
Remove Ads
Leadership Transition Amid Turbulence
Legal and Regulatory Headwinds
Analysts Split: Crash or Correction?
Novo Nordisk: Denmark's global pharma giant
Tired of too many ads?
Remove Ads
Key Innovative Advances Bolster Long-Term Outlook
Amycretin – Dual-Action Obesity Drug: Phase 1b/2a trials show 22% average body weight loss over 36 weeks, sparking a ~12% stock bump.
CagriSema – Record Weight Loss in Phase III: Achieved 20.4% weight reduction in obese adults and 13.7% in type 2 diabetes patients.
Oral Semaglutide & Amycretin: Oral formulations are under U.S. regulatory review, potentially broadening adoption.
$2.2B Septerna Partnership: Four programs targeting obesity, type 2 diabetes, and cardiometabolic diseases.
Insulin Icodec (Awiqli) – Once-Weekly Insulin: Approved in Canada, EU, and Japan, improving patient adherence.
NNC2215 – Glucose-Sensitive 'Smart' Insulin: Adjusts activity based on blood sugar, reducing hypoglycemia risk.
Alhemo (Concizumab) – Hemophilia Treatment: FDA-approved July 2025 for A and B types.
AI and Rare Disease Expansion: Collaborations with Heartseed, Ventus Therapeutics, and megaTAL platform targeting cardiovascular, MASH, and CKD therapies.
So, Is This a 'Nokia Moment'?
Summary Snapshot
Indicator Status Sales & Profit Guidance Significantly lowered; investor reaction strongly negative Competition & Market Threats Rising; compounded drugs and Eli Lilly products erode share Leadership & Strategy New CEO; strategic clarity still evolving Legal & Regulatory Risks Class-action lawsuit; compounding disputes add uncertainty Valuation & Sentiment Deeply discounted; mix of caution and opportunistic value Long-term Outlook Not terminal; pipeline and global expansion offer growth levers
Investor Takeaways
Defensive stance: Exercise caution until guidance execution and competitive dynamics are clearer.
Exercise caution until guidance execution and competitive dynamics are clearer. Value opportunity: Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones.
Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Catalysts to watch: CEO performance, legal outcomes, regulatory action on compounding, and international R&D breakthroughs.
FAQs:
Novo Nordisk (NYSE: NVO) closed at $50.39 on Thursday, down $0.51 (-1%), extending its staggering decline from a year-high of $139.74. Investors are questioning whether the Danish pharmaceutical giant is approaching its own 'Nokia moment'—a pivotal inflection point where market dominance is challenged by nimble competitors and shifting industry dynamics.On, Novo Nordisk lowered itsfrom. Operating profit (EBIT) growth was also trimmed to. The announcement triggered a, wiping out roughlyInvestors had expected continued dominance in the lucrative obesity and diabetes markets, but the downgrade sent an unmistakable warning: growth is slowing, and the competitive landscape is shifting rapidly.Novo Nordisk's blockbuster drugsandhave faced growing headwinds:These trends highlight a: traditional competition and unregulated compounding pharmacies undermining pricing power.Longtime CEOstepped down on, passing the reins to. The new CEO faces immediate challenges: stabilizing sales, defending market share, and restoring investor confidence.Market watchers emphasize that leadership changes at such a sensitive moment can either signal a bold strategic pivot or deepen uncertainty, depending on how quickly Doustdar asserts his vision.Novo Nordisk is also navigating U.S. legal scrutiny. A class-action lawsuit claims the company misled investors about competitive risks and overstated growth prospects.Financial institutions are taking note: UBS downgraded NVO to 'neutral' and cut its target price from 600 to 340 Danish kroner, warning that competitive and compounding pressures are 'here to stay.'Market opinion is divided. Some analysts foresee additional downside, while others highlight support near $47.50 as a potential stabilization point. Contributors on Seeking Alpha argue that the sell-off may have priced in worst-case scenarios, leaving room for a measured recovery if Novo's R&D pipeline delivers next-generation weight-loss drugs or accelerates global expansion.Novo Nordisk started its journey in Denmark in the 1920s, when two small companies—Nordisk and Novo—were founded to make insulin for people with diabetes. In 1989, the two merged to form Novo Nordisk as we know it today. The company's largest owner is the Novo Nordisk Foundation, which holds nearly a third of the shares but controls more than three-quarters of the voting rights.Headquartered in Bagsværd, just outside Copenhagen, Novo Nordisk has grown into one of the world's most valuable pharmaceutical companies. In mid-2025, it's worth around, although last year it briefly touched almost, putting it among the most valuable companies on the planet.At home, its impact is hard to overstate. Novo Nordisk is Denmark's biggest taxpayer, a major exporter, and an economic powerhouse—at one point its market value was larger than Denmark's entire GDP. Today, it's not just a national success story but a global leader in diabetes, obesity, and rare disease treatments.Despite short-term headwinds, Novo Nordisk is pursuing multiple growth avenues:These developments suggest Novo's, providing potential long-term catalysts.Not exactly. While Novo Nordisk faces heightened competition, slowing growth, leadership changes, and legal pressures, it retains robust cash flows, a dominant market footprint, and a promising pipeline.Short-term turbulence is clear. Yet a full-scale Nokia-style collapse is unlikely given Novo's strategic assets and global reach. The company is navigating a near-term storm, but its innovation engine and expansion efforts leave the door open for recovery.Novo Nordisk is at a critical crossroads. The company isn't collapsing, but it's clear that the weight-loss and diabetes markets are no longer uncontested territory. How the company navigates competition, regulation, and innovation in the coming months will determine whether this is a temporary stumble—or the start of a deeper transformation.The stock fell after 2025 sales guidance cuts and rising competition from Eli Lilly drugs and compounded versions.Competing drugs and pharmacy compounding have reduced market share and investor confidence.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
an hour ago
- Hindustan Times
Weight-Loss Drugs Have a Surprising Foe: Fat Activists
In the world of fat activism, the 'O-words'—overweight and obesity—are expressly verboten. That's because advocates and 'fat studies' scholars want to destigmatize and accommodate fatness—their preferred term—and push back against the view that overweight or obese people are somehow abnormal or diseased. Now a third problematic O-word has emerged: Ozempic. From the perspective of these activists and scholars, the hype around GLP-1 agonists, for which Ozempic has become the catchall term, only dials up the pressure to lose weight. It's one thing for an obese person to refuse to undergo bariatric surgery, which involves hospitalization, complications and a significant recovery. But to resist a weekly home injection? That can really test peoples' sympathy. 'Ozempic is 100% making things worse for us,' said Tigress Osborn, executive director of the National Association to Advance Fat Acceptance (NAAFA), an advocacy group founded in 1969. 'It's created an even louder public narrative that you could just solve all your problems by taking this magical drug, and if you don't take it, well then, you deserve what you get.' 'Ozempic is 100% making things worse for us,' said Tigress Osborn, executive director of the National Association to Advance Fat Acceptance, pictured in July. These concerns contrast sharply with the latest thinking in obesity medicine, which views reframing obesity as a disease—which the American Medical Association did in 2013—as a crucial step toward destigmatization. For doctors, GLP-1s such as Ozempic, Wegovy, Zepbound and Mounjaro are breakthrough tools for addressing obesity, which increases the risk of developing other serious conditions, including type-2 diabetes and heart disease. 'We are not prosecuting people for having obesity,' said Louis Aronne, one of the founders of obesity medicine as a subspecialty and the director of the Comprehensive Weight Control Center at Weill Cornell Medicine in New York City. 'We look at treating obesity as central to helping with all their other health problems.' Patients who lose weight with GLP-1s regularly see their health markers for prediabetes and hypertension improve. They often suffer less from sleep apnea, which allows them to feel better rested and elevates their mood. This can eliminate the need for antidepressants, which can themselves cause weight gain. Over the past 60 years, obesity rates have tripled in the U.S. due in part to more sedentary lifestyles and changes in diet, including more calorie-dense ultraprocessed foods. 'Obesity experts have been trying to overcome these challenges for decades and give people better lives, and we finally feel like we're really getting somewhere,' Aronne said. The advent and ubiquity of GLP-1 drugs may mark a turning point for the treatment of obesity, but they have also widened a chasm between activists and academics and much of the rest of the world, including medical specialists. One side believes it can help people overcome obesity; the other wants to shift the focus from changing their bodies to helping them live in them. 'People think that if everyone can just take this expensive, dangerous drug, we can get rid of fat people,' said Marilyn Wann, 58, a longtime fat activist in the Bay Area, who like many activists is suspicious of GLP-1s' possible long-term side effects. 'These drugs are going through the same excitement-and-disappointment cycle we've seen with every method of intentional weight loss. It just creates more work for fat activists.' Obesity's toll Certain facts are indisputable. Four in 10 adults in the U.S. have a body-mass index or BMI over 30. The financial costs are significant. The Centers for Medicare and Medicaid Services recently estimated that obesity is associated with approximately $385 billion in health spending in 2024. According to a recent paper in JAMA, employees with obesity have seven times the medical claims costs and 11 times the indemnity claims costs of those with a healthy weight. They file twice as many worker compensation claims. These costs correspond with obesity's significant health consequences, which include osteoarthritis, hyperlipidemia and other chronic diseases. Obesity-related complications include incontinence, asthma, psoriasis, reflux and kidney disease. According to a 2023 paper in the journal Nature, roughly 8% of all medical expenditures in the U.S. are associated with the treatment of obesity. Weight loss expenditures are similarly outsized. According to Grand View Research, the weight loss industry was $142.58 billion in 2022 and is projected to reach $298.66 billion by 2030. UBS estimates the GLP-1 market alone will grow to $126 billion in sales by 2029. Other aspects of obesity are less well understood. While there's a consensus that genetics, environment, insulin and other hormones play a role, no one quite knows how, or why some people become obese in the first place while others don't. Dr. Caroline Apovian, with patient Natasha Monahan at the Center for Weight Management and Wellness at Brigham and Women's Hospital, said she often sees patients weep with relief when she explains that obesity is a disease. Fat activists and scholars argue that a causal relationship between obesity and its associated maladies has yet to be definitively established, and that obesity itself is not a disease. In their view, it is inaccurate and unhelpful to stigmatize overweight people as inherently ill. Fat people, they point out, can be just as healthy as thin people, and diseases like hypertension can afflict anyone, regardless of weight. Obesity doctors see rejecting the disease framework as counterproductive. 'I don't think we should be using the argument that we don't know the etiology of obesity to say that it's not a disease,' said Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital in Boston. 'We have incredibly good data showing that excess fat tissue causes inflammation, heart disease and diabetes.' She bristles at efforts to claim that obesity doesn't raise the risk for complications: 'that is simply not the case.' Apovian acknowledged that some heavy people, including Sumo wrestlers and other athletes, are 'very healthy,' but noted that 'the majority of people with high BMIs are not.' In her practice, she said, patients cry happy tears and weep with relief when she explains that they have a disease, that a malfunction in their system is sending false signals around hunger and satiety. Deborah McPhail, a medical sociologist at the University of Manitoba, understands that sense of relief. 'We as individuals internalize this notion that we have failed ourselves, our family, our society, our public healthcare system because we have 'allowed' ourselves to become a certain weight and therefore a burden,' she said. 'To be told, 'This is beyond you, you don't have control over it' is really important for people to hear.' Activists believe that some of the health problems afflicting the overweight are products of a biased healthcare system that treats their bodies as problems in themselves. 'The unfortunate reality is that a lot of the time, fat people don't get the care they need, which can result in healthcare disparities,' said Ani Janzen, operations and project leader at the Association for Size Diversity in Health, one of several organizations that address fat bias in medicine. 'It's an awful Catch-22 because those disparities are then used to enforce the idea that larger people are in worse health than people are in smaller bodies.' Four in 10 adults in the U.S. have a body-mass index or BMI over 30. The Centers for Medicare and Medicaid Services recently estimated that obesity is associated with approximately $385 billion in health spending in 2024. Pamela Mejia, a researcher who conducted a study on fat bias in the media for NAAFA, is familiar with this prejudice. 'I have a doctor who is convinced that everything that happens to me, from a sprained ankle to a migraine, would be helped if I lost weight,' she said. 'Once I fell and bruised myself hiking and the doctors said, 'It would be better if you lose weight.' I just fell off a mountain! Does he think the mountain attacked me because I'm fat?' Nearly every fat activist has similar nightmare stories. Tigress Osborn recalls being pressured to have weight-loss surgery before undergoing a medically necessary hysterectomy. Then there are the smaller but repeated indignities confronted during routine medical visits. The absence of larger chairs in the waiting room. Hospital robes that won't fully cover their naked bodies. Equipment ranging from blood-pressure cuffs to MRI machines that cannot accommodate them. Orthopedic surgeons who refuse to do knee or hip replacements because they believe it will be too complicated or that body weight will compromise recovery. Doctors who immediately assume the reason for any visit is to lose weight and if that's not why they're there, well, it should be. No wonder overweight and obese people avoid or delay healthcare services, a fact backed by multiple studies. Either they are embarrassed by their weight or want to avoid being lectured about it. They put off cancer screenings and other tests, which some believe contribute to higher mortality rates among overweight people. Obesity doctors concede that the medical profession has a long way to go in how it approaches excess weight. Not only are more specialists needed, but doctors across the field need to be better trained. Apovian described an obese man in his 60s who couldn't move his legs, and a doctor had written on his chart, 'Patient didn't want to move his legs.' By the time doctors realized the patient had an abscess blocking his spinal cord, he was paralyzed. In 2022, when leading U.S. organizations dedicated to obesity medicine gathered to discuss treatment and prevention, their consensus statement acknowledged that 'Bias and stigmatization directed at people with obesity contributes to poor health and impairs treatment.' Losses and gains Fat studies, an interdisciplinary field that arose in the 1990s, focuses on what it calls 'weight-based oppression' and those who benefit from it. It criticizes the weight-loss industry for repeatedly selling quick fixes that help perpetuate weight cycling in a drive for profit. Fen-Phen, a 1990s diet drug that was recalled after it was shown to cause life-threatening heart problems, serves as a cautionary tale. Like ethnic studies and queer studies, fat studies was inspired by activism and organized around identity, incorporating aspects of social sciences, the arts and the humanities. In the language of fat studies, to 'fatten' an issue means to examine it through the lens of the fat justice movement. Scholars are now 'fattening' GLP-1s. One fear is an increased pressure to lose weight and a demonization of those who don't, despite the fact that GLP-1s are ineffective in 10-15% of patients. Even when successful, the drugs tend to yield a weight loss of 5% to 20%, which won't transform someone who weighs 350 pounds into a thin person. Much of the work of fat studies scholars focuses on stigma, building on 20th-century sociologist Erving Goffman's pioneering theory that stigmas around 'guilty' traits like obesity result in stronger biases than ones that are 'not your fault,' such as schizophrenia. A general awareness of unconscious biases has grown in recent years, but body size remains an outlier. Research has shown that weight discrimination is nearly as common as race discrimination, and stronger against women than men. 'The most pressing issue to me is how amazingly negative and gratuitous the negative stereotypes are against fat people and all the daily ways in which this bias is made clear,' Esther Rothblum, a professor emerita of psychology at San Diego State University and former editor of Fat Studies, an academic journal, told me. 'People say things about fat people that they would never say about black or elderly or gay people. It's very hard to be a member of any oppressed group in society but when it comes to fatness, people don't even see a problem with their prejudice.' Of course, fat activists, like all identity campaigners, don't speak for everyone they aim to represent. Many overweight people find the movement's preferred word, 'fat,' shaming. Plenty still want to escape what they see as an emotional and medical burden. For Tommy Tomlinson, pictured in 2018, taking GLP-1s has proven 'transformative' in how he views food and weight. Tommy Tomlinson, author of the 2019 memoir 'The Elephant in the Room: One Fat Man's Quest to Get Smaller in a Growing America,' has lost 58 pounds since he began taking GLP-1s last year. For him, the change has been more than physical. 'The constant food noise in my head, always thinking about the next meal, looking up the menu for the place you're going to that night—all that has disappeared,' he told me. 'It's an incredibly transformative thing in my life.' Tomlinson described a conversation he once had with Lee Kaplan, an obesity doctor and pioneer in the field. Kaplan asked Tomlinson if after being on the drugs for a while, he believed there was a chemical component to losing weight. Tomlinson said he did. Could this also mean, Kaplan asked, that something chemical in his body made Tomlinson gain all that weight in the first place? 'I hadn't thought about it in those clear and direct terms before,' Tomlinson recalled. 'It was shattering in a way but also comforting. To be told, 'It's not your fault.'' The fracas over whether a slimmed down Lizzo or Kelly Clarkson has betrayed the body positivity movement may garner more attention, but activists readily acknowledge that these drugs offer real relief to some people. The more important point, they maintain, is that regardless of the successes GLP-1s bring to any one individual, the larger problem of how fatness is handled socially, medically and economically persists. 'My goal isn't to stop people from wanting to lose weight,' Osborn of NAAFA told me. Instead, it's 'to reach more people with the knowledge that you don't have to beat yourself up over being in this body, that we can work toward creating a world where people can live freely in the bodies they are in.' That kind of message, she says, 'offers that same sense of relief—but delivers it to everyone.' Weight-Loss Drugs Have a Surprising Foe: Fat Activists Weight-Loss Drugs Have a Surprising Foe: Fat Activists Weight-Loss Drugs Have a Surprising Foe: Fat Activists
Mint
7 hours ago
- Mint
European Stocks Eye March Closing High Before US-Russia Meeting
European stocks rose, approaching March's record closing high, as investors looked ahead to the Trump-Putin summit and key US economic data. The Stoxx Europe 600 Index gained for a fourth day as it advanced 0.2% by 10:35 a.m. in London. Mining and chemical sectors outperformed, while personal care and industrial stocks were the biggest laggards. Technology also underperformed as a weak report by America's Applied Materials Inc. weighed on chip equipment stocks including ASML Holding NV. Elsewhere, Danish jeweler Pandora A/S sank 13% after its revenue missed the average analyst estimate. Shares in NKT A/S climbed 6.8% after the electrical component maker upgraded its full-year guidance. Much of the focus Friday is on the meeting between Donald Trump and Vladimir Putin in Alaska, with investors looking for signs of progress in ending the war in Ukraine. American retail sales figures due earlier, meanwhile, will provide the latest clues on the health of the economy. Florian Ielpo, head of macro at Lombard Odier Investment Managers, said any progress in ceasefire negotiations in Ukraine would be 'a positive for the market' as investors aren't currently positioned for such an outcome. Europe's stock benchmark has gained this month as optimism around Federal Reserve rate cuts overshadowed concerns about an economic slowdown. The Stoxx 600 is on track for the highest level since March on a closing basis. Still, a Bloomberg survey of strategists showed they expect only small gains into the year end. The benchmark is expected to end 2025 at 556 points, according to the average of 17 strategists, relatively unchanged from current levels. Meanwhile, the UK's FTSE 100 Index hit an all-time record high before surrendering gains of as much as 0.5%. For more on equity markets: You want more news on this market? Click here for a curated First Word channel of actionable news from Bloomberg and select sources. It can be customized to your preferences by clicking into Actions on the toolbar or hitting the HELP key for assistance. To subscribe to a daily list of European analyst rating changes, click here. With assistance from Michael Msika and Henry Ren. This article was generated from an automated news agency feed without modifications to text.
Hindustan Times
a day ago
- Hindustan Times
FDA launches festive campaign to ensure food standards in the state
Mumbai: The Maharashtra Food and Drug Administration (FDA) on Monday launched a special campaign titled 'San Maharashtracha, Sankalp Anna Surakshathika Abhiyan,' to ensure hygiene and safety standards in the food sold during the upcoming festive seasons of Ganeshotsav, Eid, Navratri, Dussehra and Diwali in the state from August 11 to October 25. The campaign includes sudden inspections of eateries to keep in check food adulteration and ensure compliance with hygiene standards. The authority is also set to organise workshops to spread awareness about the standards to be met. FDA launches festive campaign to ensure food standards in the state The initiative was launched on Monday by the FDA secretary Dheeraj Kumar, along with FDA commissioner Rajesh Narvekar and senior department officials at the Yashwantrao Chavan Centre, followed by a training session for food professionals, aiming at educating traders on hygiene practices and legal compliance during the high-demand festive period. 'During festivals, the demand for sweets, modaks, faral and prasad skyrockets. This is when the risk of adulteration increases, as some traders may cut corners due to supply shortages,' FDA secretary Dheeraj Kumar said. Food businesses should strictly follow food safety standards, avoid malpractices, and ensure products are wholesome and hygienic, he added. 'We are increasing the number of food testing labs in the state. We are also working on providing manpower for the department.' FDA commissioner Rajesh Narvekar said, 'Adulteration is often detected when market demand exceeds supply. Through our training, we hope traders will comply fully with the law so that festivals can be celebrated without compromising health.' As part of the campaign, workshops on food hygiene will be conducted for those handling mandals, sweet manufacturers, and women's self-help groups that prepare festive foods. The authority will also carry out surprise inspections of food outlets, sweet shops, street vendors and production units across the state, including Mumbai, Pune, Nagpur and Chhatrapati Sambhajinagar.
